Three‐year outcomes of peripheral blood mononuclear cells vs purified CD34+ cells in the treatment of angiitis‐induced no‐option critical limb ischemia and a cost‐effectiveness assessment: A randomized single‐blinded noninferiority trial

Three‐year outcomes of peripheral blood mononuclear cells vs purified CD34+ cells in the treatment of angiitis‐induced no‐option critical limb ischemia and a cost‐effectiveness assessment: A randomized single‐blinded noninferiority trial

Abstract For patients with angiitis‐induced critical limb ischemia (AICLI), cell transplantation, such as purified CD34+ cells (PCCs) and peripheral blood mononuclear cells (PBMNCs), is gradually being used as a promising treatment. This was the first randomized single‐blinded noninferiority trial (...

Full description

Bibliographic Details
Main Authors: Hao Liu, Tianyue Pan, Yuan Fang, Gang Fang, Yifan Liu, Xiaolang Jiang, Bin Chen, Zheng Wei, Shiyang Gu, Peng Liu, Weiguo Fu, Zhihui Dong
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Stem Cells Translational Medicine
Subjects:
adult stem cells
angiogenesis
CD34
cellular therapy
Online Access:https://doi.org/10.1002/sctm.20-0033

Similar Items

Similar Items